Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Validation of the 16-Gene Recurrence Score in patients with locoregional, high-risk renal cell carcinoma from a phase 3 trial of adjuvant sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 May 17. pii: clincanres.0323.2018. doi: 10.1158/1078-0432.CCR-18-0323. [Epub ahead of print]

PMID:
29773662
2.

A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.

Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE.

J Urol. 2018 Mar 7. pii: S0022-5347(18)42488-3. doi: 10.1016/j.juro.2018.03.004. [Epub ahead of print]

PMID:
29524506
3.
4.

Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.

Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, Berse B, Kemeter MJ, Febbo PG, Dash A.

Am J Manag Care. 2018 Jan;24(1 Suppl):S4-S10.

5.

Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).

Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR.

PLoS One. 2017 Oct 10;12(10):e0185535. doi: 10.1371/journal.pone.0185535. eCollection 2017.

6.

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.

Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, Presti JC.

Eur Urol. 2018 Jan;73(1):129-138. doi: 10.1016/j.eururo.2017.09.013. Epub 2017 Oct 6.

PMID:
28988753
7.

Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop.

Hughes KS, Ambinder EP, Hess GP, Yu PP, Bernstam EV, Routbort MJ, Clemenceau JR, Hamm JT, Febbo PG, Domchek SM, Chen JL, Warner JL; OPO Workshop Members.

J Clin Oncol. 2017 Sep 20;35(27):3153-3159. doi: 10.1200/JCO.2017.74.1744. Epub 2017 Jul 24.

PMID:
28737972
8.

Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.

Eure G, Germany R, Given R, Lu R, Shindel AW, Rothney M, Glowacki R, Henderson J, Richardson T, Goldfischer E, Febbo PG, Denes BS.

Urology. 2017 Sep;107:67-75. doi: 10.1016/j.urology.2017.02.052. Epub 2017 Apr 25.

9.

Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.

Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D, Denes B, McCall M, Shindel AW, Dubeck F.

Rev Urol. 2016;18(3):123-132.

10.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

11.

Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.

Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, Klein EA.

Oncotarget. 2016 Jun 7;7(23):33855-65. doi: 10.18632/oncotarget.8944.

12.

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ.

Urology. 2016 Mar;89:69-75. doi: 10.1016/j.urology.2015.12.008. Epub 2015 Dec 23.

13.

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA.

J Nucl Med. 2015 Mar;56(3):354-60. doi: 10.2967/jnumed.114.146936. Epub 2015 Jan 29.

14.

A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.

Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW.

Rev Urol. 2014;16(4):172-80.

15.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.

16.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

17.

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.

Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. doi: 10.1038/pcan.2013.37. Epub 2013 Dec 24.

18.

Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Spritzer CE, Afonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A, Madden JF, Roy Choudhury K, Febbo PG, George DJ.

Radiology. 2013 Dec;269(3):816-23. doi: 10.1148/radiol.13121782. Epub 2013 Oct 28.

19.

The current and future role of sequence-based analysis in prostate cancer treatment.

Kim W, Febbo PG.

Per Med. 2013 May;10(3):257-273. doi: 10.2217/pme.13.13.

PMID:
29768744
20.

Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.

Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ.

Prostate. 2013 May;73(7):754-62. doi: 10.1002/pros.22619. Epub 2012 Nov 28.

21.

Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.

Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, Taylor BS, Georgiev SG, Coetzee GA, Ohler U, Furey TS, Crawford GE, Febbo PG.

Genome Biol. 2012 Oct 3;13(10):R88. doi: 10.1186/gb-2012-13-10-r88.

22.

Predictive biomarkers in advance of a companion drug: ahead of their time?

Kelley RK, Atreya C, Venook AP, Febbo PG.

J Natl Compr Canc Netw. 2012 Mar;10(3):303-9.

PMID:
22393192
23.

Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.

Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS.

Mol Cancer Ther. 2012 Jul;11(7):1500-1509. doi: 10.1158/1535-7163.MCT-11-0937. Epub 2012 Feb 16.

24.

An animal model of MYC-driven medulloblastoma.

Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2012 Feb 14;21(2):155-67. doi: 10.1016/j.ccr.2011.12.021.

25.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16.

PMID:
22203777
26.

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML.

J Natl Compr Canc Netw. 2011 Nov;9 Suppl 5:S1-32; quiz S33.

PMID:
22138009
27.

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW.

J Urol. 2012 Jan;187(1):103-8. doi: 10.1016/j.juro.2011.09.040. Epub 2011 Nov 16.

PMID:
22088334
28.

Immune signatures predict prognosis in localized cancer.

Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG.

Cancer Invest. 2010 Aug;28(7):765-73. doi: 10.3109/07357900903095755.

29.

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA.

Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25.

30.

MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy.

Balakumaran BS, Herbert JT, Febbo PG.

Autophagy. 2010 Feb;6(2):281-2. Epub 2010 Feb 10.

PMID:
20026909
31.

Cancer gene profiling in prostate cancer.

Foye A, Febbo PG.

Methods Mol Biol. 2010;576:293-326. doi: 10.1007/978-1-59745-545-9_15.

PMID:
19882268
32.

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG.

Cancer Res. 2009 Oct 1;69(19):7803-10. doi: 10.1158/0008-5472.CAN-09-0910. Epub 2009 Sep 22.

33.

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG.

Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Review.

34.

Genomic approaches to outcome prediction in prostate cancer.

Febbo PG.

Cancer. 2009 Jul 1;115(13 Suppl):3046-57. doi: 10.1002/cncr.24350. Review.

35.

Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer.

Febbo PG.

J Clin Oncol. 2009 Jul 1;27(19):3088-90. doi: 10.1200/JCO.2008.20.9783. Epub 2009 May 26. Review. No abstract available.

PMID:
19470924
36.

The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model.

Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ.

Cancer Prev Res (Phila). 2009 Jun;2(6):557-65. doi: 10.1158/1940-6207.CAPR-08-0188. Epub 2009 May 26.

37.

A genomic strategy to elucidate modules of oncogenic pathway signaling networks.

Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR.

Mol Cell. 2009 Apr 10;34(1):104-14. doi: 10.1016/j.molcel.2009.02.030.

38.

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M.

J Natl Cancer Inst. 2009 Apr 1;101(7):519-32. doi: 10.1093/jnci/djp030. Epub 2009 Mar 24.

39.

Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.

J Clin Oncol. 2009 Apr 20;27(12):2022-9. doi: 10.1200/JCO.2008.17.2882. Epub 2009 Mar 16.

PMID:
19289629
40.

Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma.

Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2009 Feb 3;15(2):135-47. doi: 10.1016/j.ccr.2008.12.016. Erratum in: Cancer Cell. 2009 Sep 8;16(3):267.

41.

NCCN Task Force Report: mTOR inhibition in solid tumors.

Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB 3rd, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ Jr, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y.

J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2. Review.

PMID:
18926092
42.

A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG.

Mol Cancer Ther. 2008 Oct;7(10):3141-9. doi: 10.1158/1535-7163.MCT-08-0642. Erratum in: Mol Cancer Ther. 2012 May;11(5):1214-5.

43.

No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.

Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, Ma J.

Prostate. 2008 Sep 15;68(13):1416-20. doi: 10.1002/pros.20797.

44.

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL.

J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
18612148
45.

Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo.

Oltean S, Febbo PG, Garcia-Blanco MA.

Clin Exp Metastasis. 2008;25(6):611-9. doi: 10.1007/s10585-008-9186-y. Epub 2008 Jun 4.

46.

Modeling cancer progression via pathway dependencies.

Edelman EJ, Guinney J, Chi JT, Febbo PG, Mukherjee S.

PLoS Comput Biol. 2008 Feb;4(2):e28. doi: 10.1371/journal.pcbi.0040028.

47.

Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis.

Febbo PG, Mulligan MG, Slonina DA, Stegmaier K, Di Vizio D, Martinez PR, Loda M, Taylor SC.

BMC Genomics. 2007 Dec 18;8:461.

48.

Genomic signatures associated with the development, progression, and outcome of prostate cancer.

Mendiratta P, Febbo PG.

Mol Diagn Ther. 2007;11(6):345-54. Review.

PMID:
18078352
49.

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A.

J Clin Oncol. 2007 Oct 1;25(28):4350-7. Retraction in: J Clin Oncol. 2010 Dec 10;28(35):5229. Erratum in: J Clin Oncol. 2010 Jun 1;28(16):2805.

PMID:
17906199
50.

Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.

Li W, Wu CL, Febbo PG, Olumi AF.

Am J Pathol. 2007 Oct;171(4):1189-98. Epub 2007 Aug 16.

Supplemental Content

Loading ...
Support Center